Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27. It is also developing CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody selectively targeting CCR8, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, an antibody targeting human ILT4 designed to improve anti-PD-1 clinical benefit by transforming an unfavorable TME to a more favorable TME. In addition, the company's licensed immuno-oncology programs include NZV930, an antibody designed to inhibit cluster of differentiation 73; and GSK4381562, an antibody targeting CD112R for the treatment of solid tumors. Further, it offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. It collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc., as well as Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
| 0.698 | |
| 0.6786 | |
| - | |
| 0.698 | |
| 0.6786 | |
| 0.6576-3.405 | |
| 79 314 K | |
| 115 M | |
| 308 M | |
| 0.654 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
The latest analyst coverage could presage a bad day for Coherus BioSciences, Inc. (NASDAQ:CHRS), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholde...
Coherus BioSciences, Inc. – Transaction aligns to Coherus’ strategic focus on oncology – – Conference call Monday, January 22, 2024, at 8:30 a.m. Eastern Time – REDWOOD CITY, Calif., Jan....
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
